06-03-05

1.FW

Express Mail No.: EV452775245US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Swiercz et al.

Confirmation No.:

8301

Serial No.:

10/506,406

Art Unit:

1653

371 Filing Date:

March 14, 2005

Examiner:

To Be Assigned

Intl. Filing Date:

March 4, 2003

AODIEIED DI ASMINOCENI

Attorney Docket No:

9471-011-999

For: M

MODIFIED PLASMINOGEN

CAM No.:

209025-999010

ACTIVATOR INHIBITOR TYPE-1 AND METHODS

BASED THEREON

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office ("Office") of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references A01-A02, B01 and C01-C44 which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant."

Copies of references **B01** and **C01-C44** are submitted herewith. Copies of References **A01-A02**, which are United States patent documents, are not submitted herewith pursuant to 37 C.F.R. § 1.98(a)(2)(ii).

Applicants request that the Examiner review all the references identified on the attached Form PTO-1449, and that they be made of record in the file history of the above-identified application.

No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made

(other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

As this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, Applicants estimate that no fee is required. Should a fee be required, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date:

June 1, 2005

Margaret B. Brivanlou 40,922
Margaret B. Brivanlou (Reg. No.)

JONES DAY

222 East 41st Street

New York, N.Y. 10017-6702

212-326-3939

Enclosures

Express Mail No. EV452775245US

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO. 9471-011-999 (CAM: 209025-999010) 10/506,406

APPLICANT
Swiercz et al.

FILING DATE GROUP ,
March 14, 2005 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,639,726	01/17/1997	Lawrence et al.			
	A02	6,303,338 B1	10/16/2001	Ni et al.			

		FOREIGN	PATENT DOCUMENTS				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
						YES	NO
B01	WO 97/39028	10/23/1997	PCT				

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C01	International Search Report dated 1/14/2004 of corresponding PCT Application No. PCT/US03/06679.		
C02	Achbarou et al., Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 1994 May 1;54(9):2372-7.		
C03	Chorostowska-Wynimko et al., A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther. 2003 Jan;2(1):19-28.		
C04	Conese et al., The urokinase/urokinase-receptor system and cancer invasion. Baillieres Clin Haematol. 1995 Jun;8(2):365-89.		
C05	Danø et al., Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139-266.		
C06	Declerck et al., Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 1988 Jan;71(1):220-5.		
C07	Declerck et al., Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem. 1988 Oct 25;263(30):15454-61.		
C08	Ellis et al., Plasminogen activation by receptor-bound urokinase. Semin Thromb Hemost. 1991 Jul;17(3):194-200.		
C09	Festuccia et al., Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Oncol Res. 1995;7(3-4):131-8.		
C10	Hajjar et al., Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem. 1990 Feb 15;265(5):2908-16.		
CII	Hekman et al., Bovine plasminogen activator inhibitor 1: specificity determinations and comparison of the active, latent, and guanidine-activated forms. Biochemistry. 1988 Apr 19;27(8):2911-8.		
C12	Hekman et al., Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem. 1985 Sep 25;260(21):11581-7.		
C13	Hoylaerts et al., Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982 Mar 25;257(6):2912-9.		
. C14	Hsueh et al., Molecular mechanisms in the hormonal regulation of plasminogen activator activity in ovarian granulosa cells and cumulus-oocyte complexes. Prog Clin Biol Res. 1988;267:227-57.		
C15	Jankun et al., Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem. 1993 Oct;53(2):135-44.		
C16	Jankun et al., Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res. 1997 Feb 15;57(4):559-63. Erratum in: Cancer Res 1998 Jan 1;58(1):179.		
C17	Jankun et al., Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator. Cancer Res. 1991 Feb 15;51(4):1221-6.		
C18	Kwaan et al., Components of the plasminogen-plasmin system in human tumor cell lines. Semin Thromb Hemost. 1991 Jul;17(3):175-82.		
C19	Lawrence et al., Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.		

	of Application No. 10/300,400
	Biochemistry. 1994 Mar 29;33(12):3643-8.
C20	Lawrence et al., Plasminogen activator inhibitors <i>in</i> Molecular Basis of Thrombosis and Hemostasis. Marcel Dekker, Inc., High et al., eds. 1995;25:517-43.
C21	Lawrence et al., Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur J Biochem. 1989 Dec 22;186(3):523-33.
C22	Levin et al., Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood. 1987 Oct;70(4):1090-8.
C23	Mayer, Biochemical and biological aspects of the plasminogen activation system. Clin Biochem. 1990 Jun;23(3):197-211.
C24	Mayer, The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit. Blood. 1990 Oct 15;76(8):1514-20.
C2:	Mimuro et al., Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem. 1989 Mar 25;264(9):5058-63.
C26	plasminogen activator inhibitor. Blood. 1987 Sep;70(3):721-8.
C2:	angiogenesis. Biochim Biophys Acta. 1988 Aug 3;948(1):67-85.
C28	urokinase. J Cell Biol. 1988 Dec;107(6 Pt 1):2437-45.
C29	1987 Dec;105(6 Pt 1):2535-41.
C30	Aug;122(3):673-84.
C3	
C32	Pöllänen et al., Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res. 1991;57:273-328.
C3:	
C34	1988;4:93-126.
C3:	12;823(1):35-65.
C30	inhibitor 1 produced in Escherichia coli. Biochemistry. 1992 Oct 20;31(41):9877-82.
C3	May-Jun;6(3):523-6.
C38	J Biol Chem. 1984 Dec 10;259(23):14914-21.
C39	for reactivation of latent plasminogen activator inhibitor-1 in vivo. Circd Res. 1990 Nov;67(5):1281-6.
C4	Wilson et al., Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior. Cell Mol Biol Res. 1993;39(8):751-60.
C4	inhibitor. J Biol Chem. 1984 Mar 25;259(6):3644-7.
C4:	Clin Chim Acta. 1983 Jan 24;127(2):279-88.
C4:	Wiman et al., The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med. 1985 Feb;105(2):265-70.
C4-	Wun et al., Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin. J Biol Chem. 1989 May 15;264(14):7862-8.

.EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, will considered. Include copy of this form with next of	the there or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not communication to applicant.
The second secon	